E
Exo Therapeutics
About Exo Therapeutics
Exo Therapeutics is a biotechnology startup that operates in the pharmaceutical industry, specifically in the development of innovative medicines. The company's primary focus is on modulating enzyme activity in the fields of oncology and inflammation. This means they are working on creating drugs that can control the activity of enzymes, which are proteins in the body that speed up chemical reactions. By doing this, they aim to treat diseases related to cancer and inflammation more effectively.
Their main product is the ExoSight™ platform, which they describe as a comprehensive tool to expand the universe of druggable enzymes. Essentially, this platform is designed to help them discover new enzymes that can be targeted with drugs. Their lead program is currently targeting TANK Binding Kinase 1 (TBK1), an enzyme involved in the immune response, for the treatment of autoimmune diseases.
Exo Therapeutics' business model revolves around the research, development, and eventual commercialization of these innovative drugs. They make money by developing these drugs and bringing them to market, either by selling them directly or through partnerships with larger pharmaceutical companies.
The company has recently made significant appointments to its executive team, including Alexandra Joseph, PhD, as Executive Vice President of Biology, and Nagesh Mahanthappa as Executive Chair. These appointments suggest the company is gearing up for significant growth and development in the near future.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Naples, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 71.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2021 | $78M | $312M | CRV · Morningside · NewPath Ventures · Casdin Capital | — |
| SERIES AOther financing | Dec 2020 | $25M | $100M | 6 Dimensions Capital · Novartis Venture Fund · Newpath Partners · CRV | — |
Growth signals
Latest recorded traffic for Exo Therapeutics is 1.7K monthly website visits, up 139.4% over the last three months. Exo Therapeutics's team declined 5.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Newpath Partners
6 Dimensions Capital
Novartis Venture Fund
CRV
Nextech Invest
Morningside
NewPath Ventures
Casdin Capital
Samsara BioCapital
BVF Partners
Other known investors2 additional known investors
Harvard University
Salk Institute for Biological Studies
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Exo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Exo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.